Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints
暂无分享,去创建一个
Cyrus Mehta | C. Mehta | H. Schäfer | Helmut Schäfer | Hanna Daniel | S. Irle | Hanna Daniel | Sebastian Irle
[1] Frank Bretz,et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology , 2009, Statistics in medicine.
[2] C. Jennison,et al. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints † , 2011, Pharmaceutical statistics.
[3] P. Bauer,et al. Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.
[4] J. Coon,et al. Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors , 2007, Clinical Cancer Research.
[5] P. Bauer,et al. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections by H. Schäfer and H.‐H. Müller, Statistics in Medicine 2001; 20: 3741–3751 , 2004, Statistics in medicine.
[6] Helmut Schäfer,et al. Interim Design Modifications in Time-to-Event Studies , 2012 .
[7] T. Friede,et al. A conditional error function approach for subgroup selection in adaptive clinical trials , 2012, Statistics in medicine.
[8] Hoang Q. Nguyen,et al. A Hybrid Geometric Phase II/III Clinical Trial Design based on Treatment Failure Time and Toxicity. , 2012, Journal of statistical planning and inference.
[9] L Di Scala,et al. Time‐to‐event analysis with treatment arm selection at interim , 2011, Statistics in medicine.
[10] M. Posch,et al. Adaptive Survival Trials , 2014, 1405.1569.
[11] Bart Spiessens,et al. Adjusted significance levels for subgroup analyses in clinical trials. , 2010, Contemporary clinical trials.
[12] Peter F Thall,et al. Seamlessly Expanding a Randomized Phase II Trial to Phase III , 2002, Biometrics.
[13] C. Punt,et al. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. , 2010, Clinical therapeutics.
[14] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[15] Daniel J Sargent,et al. Integrating biomarkers in clinical trials , 2011, Expert review of molecular diagnostics.
[16] K. Gabriel,et al. On closed testing procedures with special reference to ordered analysis of variance , 1976 .
[17] H. Schäfer,et al. A general statistical principle for changing a design any time during the course of a trial , 2004, Statistics in medicine.